

Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy

M Tanioka^{*,1,2}, C Shimizu¹, K Yonemori¹, K Yoshimura³, K Tamura¹, T Kouno¹, M Ando¹, N Katsumata¹, H Tsuda⁴, T Kinoshita⁵ and Y Fujiwara¹

¹Breast and Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan; ²Medical Oncology Division, Hyogo Cancer Center, Hyogo, Japan; ³Department of Clinical Trial Design and Management, Translational Research Center, Kyoto University Hospital, Kyoto, Japan; ⁴Division of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan; ⁵Division of Breast Surgery, National Cancer Center Hospital, Tokyo, Japan

BACKGROUND: Although a pathologic complete response (pCR) after neoadjuvant chemotherapy is associated with favourable outcomes, a small proportion of patients with pCR have recurrence. This study was designed to identify factors predictive of recurrence in patients with pCR.

METHODS: A total of 449 breast cancer patients received neoadjuvant chemotherapy, and 88 evaluable patients had a pCR, defined as no evidence of invasive carcinoma in the breast at surgery. The clinical stage was II in 61 patients (69%), III in 27 (31%). All patients received taxanes and 92% received anthracyclines. Among 43 patients with HER2-positive tumours, 27 received trastuzumab. Cox regression analyses were performed to identify predictors of recurrence.

RESULTS: Median follow-up was 46.0 months. There were 12 recurrences, including 8 distant metastases. The rate of locoregional recurrence was 10.4% after breast-conserving surgery, as compared with 2.5% after mastectomy. Multivariate analysis revealed that axillary metastases (hazard ratio (HR), 13.6; $P < 0.0001$) and HER2-positive disease (HR, 5.0; $P < 0.019$) were significant predictors of recurrence. Five of six patients with both factors had recurrence. Inclusion of trastuzumab was not an independent predictor among patients with HER2-positive breast cancer.

CONCLUSION: Our study results suggest that HER2 status and axillary metastases are independent predictors of recurrence in patients with pCR.

British Journal of Cancer (2010) **103**, 297–302. doi:10.1038/sj.bjc.6605769 www.bjcancer.com

Published online 6 July 2010

© 2010 Cancer Research UK

Keywords: breast cancer; pathologic complete response; neoadjuvant chemotherapy; predictive factor; trastuzumab

Neoadjuvant chemotherapy is a widely accepted treatment not only for locally advanced breast cancer, but also for earlier-stage operable disease (van der Hage *et al*, 2001; Bonadonna *et al*, 1998; Bear *et al*, 2003). Mauri *et al* (2005) performed a meta-analysis of clinical trials comparing patients who received preoperative chemotherapy with those who received postoperative chemotherapy. Death, disease progression, and distant recurrence were equivalent in both the arms. The main advantages of neoadjuvant chemotherapy included the evaluation of the *in vivo* chemosensitivity of tumours in individual patients; minimisation of micrometastases; and surgical downstaging of tumours, allowing breast-conserving surgery (BCS) to be performed in patients who might have otherwise required a mastectomy. However, the survival advantage of neoadjuvant chemotherapy appears to be negligible (Fisher *et al*, 1997; Bonadonna *et al*, 1998; Kuerer *et al*, 2001; Wolmark *et al*, 2001).

In several studies, a pathologic complete response (pCR), defined as the absence of invasive tumour in the breast only or in the breast and axilla, correlates with a far lower risk of subsequent recurrence, as well as with improved overall survival (Fisher *et al*, 1997, 1998; Bonadonna *et al*, 1998; Morrell *et al*, 1998;

Kuerer *et al*, 1999; Chollet *et al*, 2002). Thus, efforts have been made to increase pCR rates by using more effective drugs and treatment regimens (Smith *et al*, 2002; Buzdar *et al*, 2005); the achievement of pCR has become the primary end point of many clinical studies.

Although a pCR is associated with favourable outcomes in most patients, some patients with pCR have disease recurrence. Previous studies have reported 5-year recurrence rates of 13–25% (Fisher *et al*, 1998; Morrell *et al*, 1998; Kuerer *et al*, 2001; Wolmark *et al*, 2001). Only a few studies have examined predictors of recurrence in patients who have a pCR to neoadjuvant treatment (Ring *et al*, 2004; Gonzalez-Angulo *et al*, 2005; Guarneri *et al*, 2006). We therefore retrospectively analysed predictive factors of recurrence in patients with breast cancer who achieved a pCR after neoadjuvant chemotherapy.

PATIENTS AND METHODS

Patients

This was a retrospective study of 88 evaluable patients with primary breast carcinoma who had a pCR after receiving neoadjuvant chemotherapy at National Cancer Center Hospital, Tokyo between 1996 and 2006. The follow-up period was completed

*Correspondence: Dr M Tanioka; E-mail: tanioka@hp.pref.hyogo.jp
Received 17 March 2010; revised 1 June 2010; accepted 9 June 2010;
published online 6 July 2010

in December 2008. The locoregional or distant recurrences were evaluated on physical examination, or by radiological imaging.

Histopathology

All patients were confirmed to have invasive carcinoma histologically by core needle biopsy. Surgical specimens were sectioned at 7- to 10-mm thick slices, and the pathological response was evaluated by pathologists specialised in breast pathology. The histologic type of the primary tumour was classified according to the *General Rules for Clinical and Pathological Recording of Breast Cancer*, The Japanese Breast Cancer Society (2004). The histologic grade of the tumours was classified according to the Elston–Ellis classification system (Elston and Ellis, 1991). The patients' levels of oestrogen receptor (ER, 1D5; Dako, Glostrup, Denmark), progesterone receptor (PgR, 1A6; Novocastra, Newcastle Upon Tyne, UK), and HER2 (HercepTest, Dako) were measured by immunohistochemical (IHC) analysis of paraffin-embedded tissue specimens. Oestrogen receptor and PgR were classified as positive if more than 10% of cancer cell nuclei were stained, regardless of the staining intensity. HER2-positive status was defined as IHC (3+); more than 10% of cancer cells markedly positive, or positive results of fluorescence *in situ* hybridisation (FISH) for HER2 amplification, that is, a HER2/CEP17 signal ratio of 2.0 (Vysis Pathvysion; Abbott, Chicago, IL, USA). IHC (2+) tumours, in which more than 10% of cancer cells were moderately positive, were excluded from the analysis without performing FISH test.

A wide range of criteria have been used to define pCR, and a consensus has yet to be reached. In this study, pCR was defined as no evidence of invasive carcinoma in the breast at the time of surgery in line with the criteria of the National Surgical Adjuvant Breast and Bowel Project B-18 (Wolmark *et al*, 2001) and the recommendations of Sataloff *et al* (1995). Because the presence or absence of residual ductal carcinoma *in situ* (DCIS) after preoperative therapy does not influence long-term rate of local recurrence or overall survival (Mazouni *et al*, 2007), we included patients with residual DCIS in the category of pCR.

Treatment

Neoadjuvant chemotherapy was indicated in patients with clinical stage II or III primary breast cancer whose tumours were larger than 3 cm. Although the potential benefits of adding taxanes to anthracycline-based regimens remain controversial in terms of long-term outcomes (Bear *et al*, 2006), regimens combining anthracyclines with taxanes, either sequentially or concomitantly, are widely used. In this study, neoadjuvant chemotherapy regimens included (1) four cycles of doxorubicin (DOX, 50 mg m⁻²) and docetaxel (DTX, 60 mg m⁻²) (AT), followed by additional adjuvant treatment with two cycles of AT or four cycles of intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF); (2) four cycles of fluorouracil (500 mg m⁻²)/epirubicin (100 mg m⁻²)/cyclophosphamide (600 mg m⁻²) (FEC) along with 12 weekly cycles of paclitaxel (80 mg m⁻²); (3) four cycles of doxorubicin (60 mg m⁻²)/cyclophosphamide (600 mg m⁻²) (AC) along with 12 weekly cycles of paclitaxel (80 mg m⁻²); (4) twelve weekly cycles of paclitaxel (80 mg m⁻²) only; and (5) four cycles of AC along with four cycles of DTX (60 mg m⁻²). After November 2002, patients with HER2-positive tumours received trastuzumab (initially 4 mg kg⁻¹ followed by 2 mg kg⁻¹ weekly) in combination with paclitaxel for 12 weeks. Trastuzumab was not administered post-operatively because it had not been approved for use in an adjuvant setting in Japan until 2007.

As for breast surgery, patients underwent either mastectomy ($n=40$) or BCS ($n=48$). Axillary lymph node dissection or sentinel lymph node biopsy alone was additionally performed. The decision to perform BCS was based on the ability to remove residual disease completely with optimal cosmetic results; patient

preference was also considered. Twenty-one patients (24%) received adjuvant endocrine therapy including tamoxifen, anastrozole, or both drugs for 5 years if either the pre-treatment biopsy specimen or the surgical specimen obtained after chemotherapy was positive for ER or PgR. We defined surgical margin positive if the tumour cells were directly exposed to the margin.

Postoperative radiotherapy was administered to 60 patients (68%) who had either undergone BCS or had locally advanced disease. The radiotherapy protocol was as follows: after mastectomy, patients with clinical stage III disease received radiotherapy, delivered in 2 Gy fractions to chest wall and axilla (total dose 50 Gy). After BCS, all patients received radiotherapy, delivered in 2 Gy fractions to the breast (total dose 50 Gy). A booster dose was delivered to the tumorectomy bed if the surgical margin was positive. Regardless of the surgical methods, patients with four or more positive axillary lymph nodes received radiotherapy, delivered in 2 Gy fractions to subclavicular region (total dose 50 Gy).

Clinical significance of locoregional recurrence after neoadjuvant chemotherapy

The impact of locoregional recurrence (LRR) survival after neoadjuvant chemotherapy on survival remains poorly understood. However, patients with LRR after adjuvant chemotherapy, especially those with ER-negative tumours, have substantially worse outcomes regardless of axillary node status (Wapnir *et al*, 2006; Anderson *et al*, 2009). Among patients who achieved a pCR in neoadjuvant setting in our study, the ER-negative rate was 73% and higher than that of patients in adjuvant settings. This suggests the LRR after neoadjuvant chemotherapy might be a negative prognostic factor.

Statistical analysis

Statistical analyses were performed using SAS, version 9.2 (SAS Institute Inc., Cary, NC, USA). The log-rank test was used to identify predictive factors associated with recurrence after the achievement of pCR. Then, variables with P -values of ≤ 0.20 on univariate analysis were included in the multivariate models. Multivariate analysis with a Cox proportional-hazards model was used to identify independent predictors in all 88 patients. Models were selected by stepwise forward analysis, retaining variables significant at the $\alpha=0.05$ level for the final model. The Kaplan–Meier product-limit method was used to compute recurrence-free survival according to the number of predictive factors. Recurrence-free survival was measured from the date of initial diagnosis to the date of recurrence (including LRR) or the last follow-up visit. In addition, the relations of recurrence to clinicopathological factors in the 43 patients with HER2-positive tumours were also evaluated. A Cox proportional-hazards model including variables with P -values of ≤ 0.05 on univariate analysis was used to identify independent predictors of recurrence.

RESULTS

Characteristics of patients with relapse

Of 449 patients with breast cancer who received neoadjuvant chemotherapy, 88 (20%) evaluable patients were identified as having a pCR. The median follow-up was 46 months (range, 8–115). Table 1 shows the patient and tumour characteristics. The median age was 54.5 years (range, 29–78). The median diameter of the primary breast tumour was 45.0 mm (range, 25–130). All patients received taxane-based chemotherapy, and 92% also received anthracycline-based therapy.

A total of 12 patients (13.6%) had tumour recurrence (Table 2). All recurrences were diagnosed within 32 months after initial diagnosis. Seven patients died of breast cancer within the follow-up

period. Among the six patients who had LRR, five had received BCS as primary surgery, and four had DCIS after neoadjuvant chemotherapy. LRR occurred in 5 of 48 patients (10.4%) after BCS, as compared with only 1 of 40 patients (2.5%) after mastectomy.

Predictive factors for recurrence in all 88 patients with pCR

The results of univariate analysis of predictive factors for recurrence are shown in Table 3. Variables tested for inclusion in the multivariate model were axillary lymph node metastasis at surgery, HER2 status (positive *vs* negative) and stage (III *vs* II). After controlling for these factors, axillary lymph node metastasis

(hazard ratio (HR), 13.6; 95% CI, 4.6–63.3; $P < 0.0001$) and HER2-positive disease (HR, 5.0; 95% CI, 1.3–19.3; $P < 0.019$) remained significant independent predictors of recurrence (Table 4). According to the number of independent risk factors (HER2-positive disease and axillary lymph node metastasis) for recurrence, the 5-year recurrence-free rate varied between 94.4% for no factor ($n = 36$), 89.1% for 1 factor ($n = 46$), and 0% for 2 factors ($n = 6$).

Predictive factors for recurrence among 43 patients with HER2-positive disease

Among 43 patients with HER2-positive breast cancer who had a pCR, 27 received trastuzumab. The results of the univariate analysis of predictive factors for recurrence are shown in Table 3. Variables tested for inclusion in the multivariate model were axillary lymph node metastasis at surgery, inclusion of trastuzumab, and stage (III). After controlling for these factors, only axillary lymph node metastasis (HR, 74.6 (8.0–692.9); $P < 0.0001$) remained a significant independent predictor of recurrence.

Table 1 Patient characteristics

Characteristic	All patients (N = 88) No. of patients
Age, years ≤50/>50	33/55
Clinical stage II/IIIA/IIIB,IIIC	61/18/9
Pre-treatment pathology Invasive ductal/lobular/mucinous/others	85/1/1/1
Nuclear grade 1/2/3/unknown	2/24/61/1
Hormone receptor status ER or PgR positive/both negative	23/65
HER2 status Positive/Negative	43/45
Neoadjuvant chemotherapy FEC → weekly paclitaxel (± trastuzumab) AC → weekly paclitaxel (± trastuzumab) AT (doxorubicin + docetaxel) Weekly paclitaxel (± trastuzumab) AC → docetaxel	31 (16 with trastuzumab) 30 (8 with trastuzumab) 19 7 (3 with trastuzumab) 1
Surgery Mastectomy/Breast-conserving surgery	40/48

Abbreviations: FEC = fluorouracil + epirubicin + cyclophosphamide; AC = doxorubicin + cyclophosphamide; PgR = progesterone receptor.

Table 2 Characteristics of patients with recurrence

No.	Age	Initial diagnosis			Operative information			State at recurrence			
		Tumour diameter	HER2	ER or PgR	Ax. M.	DCIS	BCS	LRR	Distant M.	Brain M.	RFS
1	39	90	–	–	–	–	–	–	+	+	8
2	33	52	–	+	–	–	+	–	+	–	26
3	62	55	+	–	–	–	+	+	+	–	26
4	29	35	+	+	–	+	+	+	+	–	30
5	58	42	+	–	–	–	+	+	+	–	32
6	55	65	+	–	+	+	–	–	+	–	32
7	63	49	+	–	+	+	–	+	–	–	18
8	36	34	–	+	+	–	–	–	+	–	20
9	49	30	+	–	+	+	–	–	+	–	21
10	56	25	+	–	+	+	+	+	–	–	21
11	50	55	+	–	+	–	+	–	+	+	29
12	71	60	–	–	+	+	+	+	–	–	32

Abbreviations: Ax. M. = axillary lymph node metastasis; M. = metastasis; BCS = breast-conserving surgery; RFS = recurrence-free survival (months); LRR = locoregional recurrence; ER = oestrogen receptor; PgR = progesterone receptor; HER2 = human epidermal growth factor 2; DCIS = ductal carcinoma *in situ*.

As expected, histopathological lymph node status was a strong predictor of recurrence in patients who had a pCR of their primary tumours. In contrast, HER2 status was found to be a predictor of recurrence for the first time. Gonzalez-Angulo *et al* (2005) studied predictive factors for distant metastasis in 226 patients with pCR. Although HER2 positivity was not a significant predictor of distant metastasis, HER2 status was unknown in 58% of the patients, and only 5% received taxane-based chemotherapy. Interactions between HER2 status and paclitaxel have been reported in an adjuvant setting, especially among patients with ER-negative tumours (Hayes *et al*, 2007). In our exploratory study, HER2 status was assessed by IHC or FISH analyses in all patients, the ER- or PgR-positive rate was low (26%), and all the patients received taxane-based therapy. The combination of these factors may have contributed to the identification of HER2 positivity as a significant independent predictor of recurrence after the achievement of a pCR.

Buzdar *et al* (2005, 2007) and Gianni (2008) reported the results of randomised trials of trastuzumab given with neoadjuvant chemotherapy to patients with HER2-positive breast cancer, and the pCR rate was significantly higher than that in the control arm. However, there are only a few, small randomised trials

Table 4 Multivariate analysis of predictors of recurrence (all 88 patients)

Characteristic	HR	P-value	95% CI
Axillary lymph node metastasis	13.6	<0.0001	4.6–63.3
HER2-positive disease	5.0	0.019	1.3–19.3

Abbreviations: HR = hazard ratio; CI = confidence interval; HER2 = human epidermal growth factor receptor 2.

Table 3 Univariate analysis of predictive factors for recurrence

Characteristic	All patients (N = 88)			HER2 positive (N = 43)		
	No.	Patients with recurrence (%)	P-value	No.	Patients with recurrence (%)	P-value
Age						
> 50 years old	55	10.9	0.28	28	17.9	0.83
≤ 50 years old	33	18.2		15	20	
Tumour diameter						
> 50 mm	30	20.0	0.22	12	25.0	0.44
≤ 50 mm	58	10.3		31	16.1	
Clinical stage						
II	61	9.8	0.09	30	13.3	0.11
III	27	22.2		13	30.8	
ER or PgR						
Positive	23	13.0	0.87	9	11.1	0.45
Negative	65	13.8		34	20.6	
HER2						
Positive	43	18.6	0.19			
Negative	45	9.1				
Nuclear grade						
3	61	14.5	0.71	28	21.4	0.49
1–2	26	11.5		15	13.3	
Type of chemotherapy						
Anthracycline + taxane	81	13.4	0.38	39	18.0	0.91
Taxane based	7	28.6		4	25.0	
Type of chemotherapy						
With trastuzumab	27	7.4	0.28	27	7.4	0.015
Without trastuzumab	61	16.4		16	37.5	
Surgery						
Mastectomy	40	12.5	0.84	21	23.8	0.48
BCS	48	14.6		23	13.6	
Residual DCIS						
Present	39	15.4	0.65	23	21.7	0.50
None	49	12.2		20	15.0	
No. of LNs examined						
≤ 10	15	14.7	0.93	7	14.3	0.79
> 10	73	13.7		36	19.4	
Axillary LN status						
Node positive	15	46.7	<0.001	6	83.3	<0.001
Node negative	73	6.9		37	8.1	

Abbreviations: ER = oestrogen receptor; PgR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; pCR = pathological complete response; BCS = breast-conserving surgery; DCIS = ductal carcinoma *in situ*; LN = lymph node.

of neoadjuvant trastuzumab, and so far no study has shown that neoadjuvant trastuzumab can improve overall survival (Rowan, 2009). Indeed, in our study, the pCR rate in patients with HER2-positive breast cancer who received neoadjuvant chemotherapy with trastuzumab was 50% (27 out of 54), which was much higher than that for the study group as a whole (20%, 88 out of 449). However, the inclusion of trastuzumab was not a significant predictor of recurrence on multivariate analysis. This is partly because trastuzumab was not administered post-operatively. The optimal duration of trastuzumab in neoadjuvant and adjuvant setting should be confirmed prospectively in randomised trials.

The demand for BCS is expected to rise as the reported rate of pCR after BCS increases. However, LRR rates after BCS in patients who received neoadjuvant chemotherapy in previous studies have varied from 2.6 to 22.6% (Mauriac *et al*, 1999; Rouzier *et al*, 2001; Peintinger *et al*, 2006). This wide variability has led to uncertainty, and the benefits of BCS have been questioned. Objective evaluation of the safety and effectiveness of BCS has been precluded by the small numbers of patients who have achieved a pCR, different criteria for determining whether BCS is indicated, and different treatment regimens. Mauri *et al* (2005) performed a meta-analysis of clinical trials comparing preoperative with postoperative chemotherapy. Although the proportion of patients with distant recurrence was equivalent in both arms, LRR was more frequent in the preoperative chemotherapy arm, with an HR of about 1.2. In our study, most cases of LRR occurred after BCS, and the proportion of patients with LRR was 10.4% after BCS, as compared with only 2.5% after mastectomy. Our study results suggest that

even after achieving a pCR, patients should be carefully followed up for LRR after BCS.

This study was retrospective and lacked a sufficient number of patients with recurrence after the achievement of a pCR to allow us to make firm recommendations for a given treatment option. Despite these limitations, some tentative conclusions can be drawn. First, our retrospective analysis showed that HER2-positive disease and axillary metastasis were independent predictors of recurrence after the achievement of a pCR at the primary site in response to neoadjuvant chemotherapy. This finding suggests that patients with HER2-positive disease and axillary metastasis may be candidates for more aggressive adjuvant therapy even after the achievement of a pCR, but this assumption must be confirmed in future clinical trials. Second, the inclusion of trastuzumab in regimens for neoadjuvant chemotherapy might not be predictive of recurrence, even though the rate of pCR among patients who received trastuzumab was much higher than that among all patients who received neoadjuvant chemotherapy. Third, the rate of LRR was higher after BCS than after mastectomy. Patients who undergo BCS should thus be closely followed up for LRR.

ACKNOWLEDGEMENTS

This study was supported by a grant for 'Validation study of pathological response criteria for neoadjuvant chemotherapy for primary breast cancer' from the Japanese Breast Cancer Society (2008).

REFERENCES

- Anderson SJ, Wapnir I, Dignam JJ, Fisher B, Mamounas EP, Jeong JH, Geyer Jr CE, Wickerham DL, Costantino JP, Wolmark N (2009) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five national surgical adjuvant breast and bowel project protocols of node-negative breast cancer. *J Clin Oncol* 27: 2466–2473
- Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. *J Clin Oncol* 21: 4165–4174
- Bear HD, Anderson S, Smith RE, Geyer Jr CE, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. *J Clin Oncol* 24: 2019–2027
- Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, Zambetti M (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. *J Clin Oncol* 16: 93–100
- Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. *J Clin Oncol* 23: 3676–3685
- Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN (2007) Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. *Clin Cancer Res* 13: 228–233
- Chollet P, Amat S, Cure H, de Latour M, Le Bouedec G, Mouret-Reynier MA, Ferriere JP, Achard JL, Dauplat J, Penault-Llorca F (2002) Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. *Br J Cancer* 86: 1041–1046
- Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. *Histopathology* 19: 403–410
- Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz Jr AB, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. *J Clin Oncol* 15: 2483–2493
- Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz Jr AB, Hoehn JL, Lees AW, Dimitrov NV, Bear HD (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. *J Clin Oncol* 16: 2672–2685
- Gianni L, Eiermann W, Semiglazov V, Manikhas GM, Lluch A, Tjulandin S, Feyereislova A, Valagussa P, Baselga J (2008) Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial. *31st San Antonio Breast Cancer Symposium (abstract 31)*; 10–14 December
- Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, Kau SW, Huang EH, Morandi P, Ocana A, Cristofanilli M, Valero V, Buzdar AU, Hortobagyi GN (2005) Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. *J Clin Oncol* 23: 7098–7104
- Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. *J Clin Oncol* 23: 5983–5992
- Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM (2006) Prognostic value of pathologic complete response after primary

- chemotherapy in relation to hormone receptor status and other factors. *J Clin Oncol* **24**: 1037–1044
- Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA (2007) HER2 and response to paclitaxel in node-positive breast cancer. *N Engl J Med* **357**: 1496–1506
- Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. *J Clin Oncol* **17**: 460–469
- Kuerer HM, Singletary SE, Buzdar AU, Ames FC, Valero V, Buchholz TA, Ross MI, Pusztai L, Hortobagyi GN, Hunt KK (2001) Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. *Am J Surg* **182**: 601–608
- Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. *J Natl Cancer Inst* **97**: 188–194
- Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, Dilhuydy JM, Bonichon F (1999) Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). *Ann Oncol* **10**: 47–52
- Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, Meric-Bernstam F, Valero V, Hortobagyi GN, Pusztai L (2007) Residual ductal carcinoma *in situ* in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. *J Clin Oncol* **25**: 2650–2655
- Morrell LE, Lee YJ, Hurley J, Arias M, Mies C, Richman SP, Fernandez H, Donofrio KA, Raub Jr WA, Cassileth PA (1998) A phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma. *Cancer* **82**: 503–511
- Peintinger F, Symmans WF, Gonzalez-Angulo AM, Boughey JC, Buzdar AU, Yu TK, Hunt KK, Singletary SE, Babiera GV, Lucci A, Meric-Bernstam F, Kuerer HM (2006) The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. *Cancer* **107**: 1248–1254
- Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR (2004) Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. *Br J Cancer* **91**: 2012–2017
- Rouzier R, Extra JM, Carton M, Falcou MC, Vincent-Salomon A, Fourquet A, Pouillart P, Boursstyn E (2001) Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. *J Clin Oncol* **19**: 3828–3835
- Rowan K (2009) Trastuzumab before breast surgery? Large trial says yes but does not quell debate. *J Natl Cancer Inst* **101**: 448–449
- Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z (1995) Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. *J Am Coll Surg* **180**: 297–306
- Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ogston KN (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. *J Clin Oncol* **20**: 1456–1466
- van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. *J Clin Oncol* **19**: 4224–4237
- Wapnir IL, Anderson SJ, Mamounas EP, Geyer Jr CE, Jeong JH, Tan-Chiu E, Fisher B, Wolmark N (2006) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. *J Clin Oncol* **24**: 2028–2037
- Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. *J Natl Cancer Inst Monogr* **30**: 96–102